Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:SIOX

Sio Gene Therapies (SIOX) Stock Price, News & Analysis

Sio Gene Therapies logo

About Sio Gene Therapies Stock (NASDAQ:SIOX)

Key Stats

Today's Range
$0.45
$0.48
50-Day Range
$0.38
$0.48
52-Week Range
$0.25
$0.50
Volume
40,400 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.

Receive SIOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sio Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

SIOX Stock News Headlines

What This Post-Election Shift Means for Your Investments
The election may be over, but its impact on financial markets is only beginning. New trends are emerging, bringing both challenges and opportunities for investors. Many of these changes are flying under the radar, yet they have the potential to reshape the financial landscape for years to come. Understanding how these shifts could affect your wealth—and what steps to take—has never been more important.
Sio Gene Therapies Inc SIOX
Sio Gene Therapies (NASDAQ: AXGT)
See More Headlines

SIOX Stock Analysis - Frequently Asked Questions

Sio Gene Therapies Inc. (NASDAQ:SIOX) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.12.

Sio Gene Therapies's stock reverse split before market open on Wednesday, May 8th 2019. The 1-8 reverse split was announced on Tuesday, May 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sio Gene Therapies investors own include Block (SQ), Digital Turbine (APPS), Palantir Technologies (PLTR), CrowdStrike (CRWD), ChargePoint (CHPT), Vuzix (VUZI) and Okta (OKTA).

Company Calendar

Last Earnings
11/12/2021
Today
11/22/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SIOX
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
No Data
Beta
N/A
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report

This page (NASDAQ:SIOX) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners